ENA-001

From WikiMD.com - Food, Medicine & Wellness Encyclopedia

(Redirected from GAL-021)

A drug for the treatment of respiratory depression


{{Drugbox | verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[4-(2,3-dichlorophenyl)piperazin-1-yl]methyl]-1,2,3,4-tetrahydroisoquinoline | image = GAL-021.svg | image2 = | width = 200 }}

ENA-001 is a pharmaceutical compound under investigation for its potential use in treating respiratory depression, a condition characterized by inadequate ventilation leading to increased blood carbon dioxide levels and decreased oxygen levels. This condition can be life-threatening and is often caused by opioid overdose, anesthesia, or other central nervous system depressants.

Mechanism of Action[edit | edit source]

ENA-001 is classified as a respiratory stimulant. It works by modulating the activity of certain ion channels in the brain that are responsible for controlling the respiratory drive. Unlike traditional treatments for respiratory depression, such as naloxone, which directly antagonize opioid receptors, ENA-001 acts through a different pathway, potentially offering a novel approach to treatment.

Clinical Development[edit | edit source]

ENA-001 is currently in the clinical trial phase, where its efficacy and safety are being evaluated. The drug is being tested for its ability to reverse respiratory depression without affecting the analgesic effects of opioids, which is a significant advantage over current treatments.

Potential Benefits[edit | edit source]

The development of ENA-001 is particularly important in the context of the opioid epidemic, where there is a critical need for effective treatments that can reverse respiratory depression without compromising pain management. Additionally, ENA-001 may have applications in surgical settings where anesthesia-induced respiratory depression is a concern.

Challenges and Considerations[edit | edit source]

While ENA-001 shows promise, there are challenges in its development. These include ensuring the drug's safety profile, determining the appropriate dosing regimen, and understanding its long-term effects. Further research is needed to fully establish its role in clinical practice.

Related Pages[edit | edit source]

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD